Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Neoplasms 4Zollinger-Ellison Syndrome 1Unspecified Childhood Solid Tumor, Protocol Specific 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Pinealoma 1Paraganglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Insulinoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Glucagonoma 1Glioma 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Hepatocellular 1Brain Stem Neoplasms 1Adult Solid Neoplasm 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × cixutumumab × Clear all
NCT01007032 2019-02-27

A Study of IMC-A12 in Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
21 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00785538 2019-01-08

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
24 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00678769 2015-11-04

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
72 enrolled
Tumor-Agnostic

Neoplasms

NCT00785941 2011-10-13

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡